Cingulate Inc已向美国证券交易委员会提交招股说明书补充文件,计划通过市场发行方式,分阶段出售总额最高达1亿美元的普通股。此次股票发行将根据市场状况和公司资金需求灵活进行,所得资金拟用于推进其核心候选药物的临床试验及一般企业用途。
Cingulate Inc已向美国证券交易委员会提交招股说明书补充文件,计划通过市场发行方式,分阶段出售总额最高达1亿美元的普通股。此次股票发行将根据市场状况和公司资金需求灵活进行,所得资金拟用于推进其核心候选药物的临床试验及一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.